[
  {
    "ts": null,
    "headline": "Assessing Zoetis (ZTS) Valuation After Recent Share Price Weakness",
    "summary": "Context for Zoetis after recent share performance Zoetis (ZTS) has seen mixed share performance recently, with a small move higher over the past month but negative returns over the past 3 months and year. This has prompted closer attention from some investors. See our latest analysis for Zoetis. At a share price of US$123.24, Zoetis has seen a 90 day share price return decline of about 16% and a 1 year total shareholder return decline of about 25%, suggesting momentum has been fading as...",
    "url": "https://finnhub.io/api/news?id=08266af8782f650e2ff1ccbedb61c81c6fcf15df397d0eed4ff2e99d3671a5f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769026159,
      "headline": "Assessing Zoetis (ZTS) Valuation After Recent Share Price Weakness",
      "id": 138199062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Context for Zoetis after recent share performance Zoetis (ZTS) has seen mixed share performance recently, with a small move higher over the past month but negative returns over the past 3 months and year. This has prompted closer attention from some investors. See our latest analysis for Zoetis. At a share price of US$123.24, Zoetis has seen a 90 day share price return decline of about 16% and a 1 year total shareholder return decline of about 25%, suggesting momentum has been fading as...",
      "url": "https://finnhub.io/api/news?id=08266af8782f650e2ff1ccbedb61c81c6fcf15df397d0eed4ff2e99d3671a5f2"
    }
  },
  {
    "ts": null,
    "headline": "Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).",
    "url": "https://finnhub.io/api/news?id=7cb03432327c799e75160764b72824223fc64675021e5bb00aa2d0c5cd99b25f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768966529,
      "headline": "Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment",
      "id": 138196182,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with Zoetis (NYSE:ZTS).",
      "url": "https://finnhub.io/api/news?id=7cb03432327c799e75160764b72824223fc64675021e5bb00aa2d0c5cd99b25f"
    }
  }
]